Skip To The Main Content
Jan 22, 2021 Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support—such as the need for ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world. Early in the pandemic, physicians around the world observed increased rates of blood clots and inflammation among COVID-19 patients which affected multiple organs and led to complications such as lung failure, heart attack and stroke. Whether providing increased doses of blood thinners routinely administered to hospitalized patients would be safe and effective was unknown at that time. Full story

Mar 19, 2020 Coronavirus Disease 2019 (COVID-19) Information for NIH Applicants and Recipients of NIH Funding

he NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared public health emergency for COVID-19. Due to the potential exceptional impact, we want to assure our recipient community that NIH will be doing our part to help you continue your research. This is a rapidly evolving situation and we will provide updated guidance and information as it becomes available. See Full Story. Full story

Mar 18, 2020 NEW FDA Guidance on COVID-19

The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States from threats including emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. F DA is committed to providing timely guidance to support continuity and response efforts to this pandemic. FDA is issuing this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic. Full story

Mar 17, 2020 StrokeNet COVID-19 Guidance

The primary concern for StrokeNet is the safety of our patients or potential patients for our ongoing trials. The second concern is the safety of our own investigators and study team members. Finally, we also want to maintain, as much as possible, the integrity of the trials to potentially benefit patients and so that the data can be used to answer the questions that the trials intended. This latter point is critical for subjects in the trial and those with the specific problem in the future. However, immediate safety issues take priority over any formal processes in ongoing trials. For example, while a current protocol may specify that a study visit needs to be in person, the FDA has guidance about the primary safety of study subjects: For more information click Full Story: Full story

Feb 27, 2020 Stroke v1.0 Common Data Elements (CDEs)

The National Institute of Neurological Disorders and Stroke (NINDS), and National Institutes of Health (NIH) recently assembled an external working group of international experts to update the Stroke v1.0 Common Data Elements (CDEs) based on user feedback and research advances. Full story

Feb 25, 2020 Washington Post - Infant Experience Strokes in Utero Causing Physical and Cognitiave Problems... New Therapies May Help

Nicole Dodds first noticed her son, Rowan, was having trouble using the right side of his body when he was about 6 months old. Babies typically use both hands to pick up toys and lift their chest off the floor at that age, but Rowan was mostly using his left arm and hand, keeping his right hand balled in a fist. Full story

Mar 06, 2019 DEFUSE 3 - DISTINGUISHED CLINICAL RESEARCH ACHIEVEMENT AWARD

The Distinguished Clinical Research Achievement Awards are presented to the top two studies that show creativity, innovation, or a novel approach that demonstrates an immediate impact on the health and well-being of patients. This means we were ranked #2 or #3 among all clinical trials performed last year— includes all areas of medicine. The #1 award went to a study that reduced HTN by instituting therapy though a network of black barbershops DEFUSE 3 results will be presented to selected members of Congress March 7th. Full story

May 24, 2018 PRESS RELEASE - TELEREHAB - UCI STUDY SHOWS IN-HOME THERAPY EFFECTIVE FOR STROKE REHABILITATION - A multisite US clinical trial compared home-based telerehabilitation program with traditional in-clinic rehabilitation therapy

May 24, 2018 - In-home rehabilitation, using a telehealth system and supervised by licensed occupational/physical therapists, is an effective means of improving arm motor status in stroke survivors, according to findings presented by University of California, Irvine neurologist Steven C. Cramer, MD, at the recent 2018 European Stroke Organisation Conference in Gothenburg, Sweden. Full story

Jan 26, 2018 NEWS & PRESS RELEASE - DEFUSE 3 - BRAIN SCAN GUIDED EMERGENCY STROKE TREATMENT

Advances in brain imaging can identify a greater number of stroke patients who can receive therapy later than previously believed, according to a new study co-led by researchers in NIH StrokeNet. The results of the "Endovascular Therapy Following Imaging Evaluation for the Ischemic Stroke (DEFUSE 3)” trial, presented at the International Stroke Conference 2018 in Los Angeles and published on Jan. 24 in the New England Journal of Medicine, demonstrated that physically removing brain clots up to 16 hours after symptom onset in selected patients led to improved outcomes compared to standard medical therapy. Click Full Story to see the published article: Full story